Signal Explorer

Nasdaq Minimum Bid Price Delisting Notice

Reverse Stock Split Effected Equity Plan Board Approval Conditional On Shareholder Vote Kol Endorsement

Indication Expansion

Executive Educational Background Disclosure Rsu Psu Vesting Schedule Disclosed Executive Transition Gratitude Statement Employee Director Compensation Waiver Cause For Termination Defined Interim Data Positive Kol Endorsement

Lead Asset Progress Clinical Trial Result Management Exodus Clinical Hold Indication Expansion

Rsu Psu Vesting Schedule Disclosed Liquidity Position Snapshot Disclosed Net Loss Reported Warrant Valued Black Scholes Cash Flow Statement Investing Activities Financing Activities Cash Flow Disclosure Operating Lease Rent Expense Disclosed Restrictive Debt Covenants Disclosure Audit Committee Independence Certification Ipo Or Capital Raising Completion Stock Option Grant Disclosed Institutional Investment Interim Data Positive Codm Segment Reporting Disclosure Fast Track Designation Received

Regulatory Designation Only Lead Asset Progress Clinical Trial Result Indication Expansion

Fast Track Designation Received Enrollment Ahead Of Schedule Fast Track Granted Interim Data Positive

Orphan Drug Designation

Audit Committee Independence Certification Nasdaq Minimum Bid Price Delisting Notice

Executive Severance Change Of Control Severance Payment Obligation

Multi Class Voting Structure Disclosed

Executive Educational Background Disclosure Form 8K Filing Disclosure Equity Plan Board Approval Conditional On Shareholder Vote Employee Director Compensation Waiver Classified Board Director Election Rsu Psu Vesting Schedule Disclosed

Management Exodus

Management Exodus

Liquidity Position Snapshot Disclosed Rsu Psu Vesting Schedule Disclosed Net Loss Reported Warrant Valued Black Scholes Operating Lease Rent Expense Disclosed Capital Raising Uncertainty Disclosed Cash Flow Statement Investing Activities Financing Activities Cash Flow Disclosure Ipo Or Capital Raising Completion Restrictive Debt Covenants Disclosure Personnel Cost Decrease Disclosure Deferred Revenue Recognition Disclosure Audit Committee Independence Certification Enrollment Ahead Of Schedule

Clinical Trial Result

Gene Therapy Aav

Lead Asset Progress

Regulatory Designation Only Clinical Trial Result Clinical Hold Indication Expansion Lead Asset Progress

Fast Track Designation Received Fast Track Granted Orphan Status Granted Enrollment Ahead Of Schedule Expanded Access Program Active Interim Data Positive Rmat Designation Received Breakthrough Therapy Granted

Orphan Drug Designation Clinical Hold Active

Reverse Stock Split Effected